What is HC Wainwright's Estimate for ADCT Q1 Earnings?

Key Points

• HC Wainwright has projected ADC Therapeutics to report earnings of ($0.34) per share for Q1 2026, maintaining a "Buy" rating with a price target of $7.00.
• ADC Therapeutics reported ($0.50) EPS for its last quarter, missing analysts' expectations, despite revenue of $18.84 million exceeding estimates.
• Several brokerages have varying ratings on ADC Therapeutics, with four analysts rating it as a Buy and a consensus target price of $7.50.

ADC Therapeutics SA (NYSE:ADCT - Free Report) - HC Wainwright issued their Q1 2026 earnings estimates for ADC Therapeutics in a note issued to investors on Thursday, October 16th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.34) per share for the quarter. HC Wainwright has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for ADC Therapeutics' current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics' Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.37) EPS.

Several other brokerages have also commented on ADCT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ADC Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada upgraded shares of ADC Therapeutics from an "outperform" rating to a "moderate buy" rating and reduced their target price for the company from $8.00 to $5.00 in a research note on Friday, June 20th. Guggenheim reaffirmed a "buy" rating and issued a $10.00 target price on shares of ADC Therapeutics in a report on Wednesday, August 13th. Finally, Wall Street Zen cut shares of ADC Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $7.50.

ADC Therapeutics Trading Down 2.3%

Shares of ADCT opened at $4.16 on Friday. ADC Therapeutics has a 1 year low of $1.05 and a 1 year high of $4.74. The stock has a 50 day simple moving average of $3.52 and a 200-day simple moving average of $2.75. The stock has a market cap of $468 million, a PE ratio of -2.65 and a beta of 1.99.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.14). The business had revenue of $18.84 million for the quarter, compared to analysts' expectations of $17.82 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ADCT. Cerity Partners LLC acquired a new position in shares of ADC Therapeutics during the first quarter valued at $25,000. Atria Wealth Solutions Inc. bought a new position in shares of ADC Therapeutics in the 1st quarter worth $28,000. Creative Planning acquired a new position in ADC Therapeutics in the second quarter valued at about $96,000. Ethic Inc. acquired a new position in shares of ADC Therapeutics during the 2nd quarter worth about $103,000. Finally, Russell Investments Group Ltd. boosted its stake in ADC Therapeutics by 136.3% during the 1st quarter. Russell Investments Group Ltd. now owns 39,688 shares of the company's stock worth $56,000 after acquiring an additional 22,894 shares during the last quarter. 41.10% of the stock is currently owned by institutional investors.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.